These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 24685447)

  • 1. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.
    Murray LJ; Lilley J; Thompson CM; Cosgrove V; Mason J; Sykes J; Franks K; Sebag-Montefiore D; Henry AM
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):406-15. PubMed ID: 24685447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy.
    Wang T; Zhou J; Tian S; Wang Y; Patel P; Jani AB; Langen KM; Curran WJ; Liu T; Yang X
    Br J Radiol; 2020 Mar; 93(1107):20190845. PubMed ID: 31904261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
    Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.
    Riches SF; Payne GS; Desouza NM; Dearnaley D; Morgan VA; Morgan SC; Partridge M
    Br J Radiol; 2014 May; 87(1037):20130813. PubMed ID: 24601648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
    Stanic S; Mathai M; Cui J; Purdy JA; Valicenti RK
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1897-902. PubMed ID: 21536391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
    van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.
    Widesott L; Pierelli A; Fiorino C; Lomax AJ; Amichetti M; Cozzarini C; Soukup M; Schneider R; Hug E; Di Muzio N; Calandrino R; Schwarz M
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1589-600. PubMed ID: 21167651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
    Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
    J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton versus photon therapy for high-risk prostate cancer with dose escalation of dominant intraprostatic lesions: a preliminary planning study.
    Ong ALK; Knight K; Panettieri V; Dimmock M; Tuan JKL; Tan HQ; Wright C
    Front Oncol; 2023; 13():1241711. PubMed ID: 38023170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy.
    Andrzejewski P; Kuess P; Knäusl B; Pinker K; Georg P; Knoth J; Berger D; Kirisits C; Goldner G; Helbich T; Pötter R; Georg D
    Radiother Oncol; 2015 Dec; 117(3):509-14. PubMed ID: 26349588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers.
    Osman SOS; Fairmichael C; Whitten G; Lundy GS; Wesselman R; Wilson ML; Hounsell AR; Prise KM; Irvine D; McGarry CK; Jain S
    Radiat Oncol; 2022 Feb; 17(1):38. PubMed ID: 35193630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra hypofractionated extended nodal irradiation using volumetric modulated arc therapy for oligorecurrent pelvic nodal prostate cancer.
    Slevin F; Thompson CM; Speight R; Murray LJ; Lilley J; Henry AM
    Med Dosim; 2021 Winter; 46(4):411-418. PubMed ID: 34148727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes.
    Yoo S; Wu QJ; Lee WR; Yin FF
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):935-42. PubMed ID: 20044214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformal irradiation of concave-shaped PTVs in the treatment of prostate cancer by simple 1D intensity-modulated beams.
    Fiorino C; Broggi S; Corletto D; Cattaneo GM; Calandrino R
    Radiother Oncol; 2000 Apr; 55(1):49-58. PubMed ID: 10788688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse and forward optimization of one- and two-dimensional intensity-modulated radiation therapy-based treatment of concave-shaped planning target volumes: the case of prostate cancer.
    Corletto D; Iori M; Paiusco M; Brait L; Broggi S; Ceresoli G; Iotti C; Calandrino R; Fiorino C
    Radiother Oncol; 2003 Feb; 66(2):185-95. PubMed ID: 12648791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megavoltage cone beam computed tomography dose and the necessity of reoptimization for imaging dose-integrated intensity-modulated radiotherapy for prostate cancer.
    Akino Y; Koizumi M; Sumida I; Takahashi Y; Ogata T; Ota S; Isohashi F; Konishi K; Yoshioka Y
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1715-22. PubMed ID: 21620584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy.
    Devlin L; Dodds D; Sadozye A; McLoone P; MacLeod N; Lamb C; Currie S; Thomson S; Duffton A
    Br J Radiol; 2020 Apr; 93(1108):20190789. PubMed ID: 31971829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: a treament planning comparison.
    Fellin F; Azzeroni R; Maggio A; Lorentini S; Cozzarini C; Di Muzio N; Fiorino C; Calandrino R; Schwarz M
    Radiother Oncol; 2013 May; 107(2):207-12. PubMed ID: 23541644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous integrated boost with stereotactic radiotherapy for dominant intraprostatic lesion of localized prostate cancer: a dosimetric planning study.
    Kim YJ; Yoon KJ; Kim YS
    Sci Rep; 2020 Sep; 10(1):14713. PubMed ID: 32895442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.
    Outaggarts Z; Wegener D; Berger B; Zips D; Paulsen F; Bleif M; Thorwarth D; Alber M; Dohm O; Müller AC
    Acta Oncol; 2020 Aug; 59(8):911-917. PubMed ID: 32436467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.